チクングニアウイルスワクチン:世界の市場機会分析・予測

◆英語タイトル:MarketVIEW: Chikungunya virus vaccines - Global vaccine commercial opportunity assessment
◆商品コード:VAZ2006004
◆発行会社(リサーチ会社):VacZine Analytics
◆発行日:2020年2月
◆ページ数:n/a
◆レポート言語:英語
◆レポート形式:Executive presentation (>200 slides.pdf) + 1 x MS-Excel forecast model(s) (.xls)
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Region PriceUSD10,995 ⇒換算¥1,143,480見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はVacZine Analytics社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
VacZine Analytics社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Chikungunya virus (CHIK) is an arthropod-borne RNA virus (arbovirus) which causes an acute illness including fever, skin rash, and incapacitating arthralgia. In some cases, the virus can cause recurrent disease (post-CHIK rheumatic disorder), neurological complications and severe neonatal disease (encephalopathy). CHIK is not generally considered a life-threatening disease, with an estimated case-fatality rate of 0.1%. However, concerns are increasing. In 2016, the Brazilian Ministry of Health recognised more than 200 deaths related to CHIK infection and during 2018/2019 a further 126 deaths were recorded across the PAHO region.
A number of potential CHIKV vaccine candidates (based on various approaches) are now in the clinical stages of development including those from Emergent BioSolutions, Themis Bio GmbH and Valneva Austria GmbH These candidates have received US and EU fast track regulatory designations underscoring their high medical need, and recently, the Coalition of Epidemic Preparedness Innovations (CEPI) has also disbursed funds to ongoing efforts. Now, regulators are considering new accelerated pathways to licensure based on immunogenicity (ICOP) rather than conducting a Phase III efficacy study. Once proven to be safe, a CHIKV vaccine could be available from 2022/23 onwards and used in vulnerable populations in both endemic public/private markets and possibly in Western travelers (profile dependent).

This MarketVIEW product is a comprehensive commercial evaluation containing an Executive Presentation (>200 slides) and 1 x MS Excel Workbook(s) (.xls) examining the potential (value/volume) of a prophylatic Chikungunya vaccine to 2035. The prospects of the vaccine in First time and Repeat Western travelers (Visiting Friends/Family and Business + Other), endemic markets (public + private) and for military/domestic stockpile use are discussed with assumptions clearly outlined. A newly engineered model for 2020 now explores a mixed vaccine schedule market whereby competitor entrance scenarios can be visualized. A full review of disease background, latest epidemiology/outbreaks and competitor/R&D activity is also provided.

THIS PRODUCT IS A SUMMARY PRESENTATION (>200 slides, .pdf form) + 1 x FORECAST MODEL(s) (.xls)

【レポートの目次】

PRODUCT CONTENTS: Published February 2020 (CAT No: VAMV005) ****This product is a summary presentation (.pdf), 1 x forecast models (.xls) Contents – Summary presentation (.pdf)3 Contents Author’s notes Executive summary [SECTION 1] Chikungunya virus vaccines: key model outputs [SECTION 2] Chikungunya virus: disease background [SECTION 3] Chikungunya virus: disease epidemiology [SECTION 4] Chikungunya virus: R&D pipeline and competitor activity [SECTION 5] Chikungunya virus: modelling commercial potential References/bibliography About VacZine Analytics Disclaimer PAGES: ~200 slides fully referenced/sourced. Available in .pdf form Contents – 1 x vaccine demand models (MS Excel-based) Worksheets = >100 interconnected



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[チクングニアウイルスワクチン:世界の市場機会分析・予測]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆